NPD8716
NPD8716 is a sodium taurocholate cotransporting polypeptide (NTCP) inhibitor with a human IC50 of 17.8 μM. NPD8716 interacts with NTCP, blocks the binding of HBV preS1 to NTCP, impairs NTCP-mediated bile acid uptake, inhibits NTCP transporter activity, and blocks the attachment of viruses to host hepatocytes. NPD8716 inhibits the entry of HBV and HDV into host cells. NPD8716 can be used in studies related to hepatitis B virus infection and hepatitis D virus infection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 956944-02-8
- 화학식: C23H31NO6S
- 분자량:449.56
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
17.8 μM
|
Inhibition of NTCP-mediated [3H]-taurocholic acid uptake in human hepatocyte-derived HepG2-hNTCP-C4 cells incubated for 15 min in a sodium-containing buffer at 37 °C measured by intracellular radioactivity.
Inhibition of NTCP-mediated [3H]-taurocholic acid uptake in human hepatocyte-derived HepG2-hNTCP-C4 cells incubated for 15 min in a sodium-containing buffer at 37 °C measured by intracellular radioactivity.
|
29426822 |
In Vitro
NPD8716 directly binds to recombinant NTCP-His in a dose-dependent manner, as detected by SPR analysis[1].
NPD8716 dose-dependently inhibits NTCP-mediated bile acid uptake in HepG2-hNTCP-C4 cells in vitro, with an IC50 of 17.8 μM[1].
NPD8716 (25-200 μM; 16 h coincubation with HBV, followed by 12 days of culture without compound) inhibits HBV infection in HepG2-hNTCP-C4 cells in a dose-dependent manner, with no cytotoxicity[1].
NPD8716 (40 μM for the first 3 days, then switched to 20 μM until day 24 or day 36; or continuously administered at 60 μM until day 24) inhibits the spread of HBV in freshly isolated primary human hepatocytes when administered at the time of inoculation or 48 h post-inoculation[1].
NPD8716 (200 μM; 6 days) does not inhibit HBV replication in Hep38.7-Tet cells, indicating that its anti-HBV activity does not target the viral replication process[1].
NPD8716 (200 μM; 30 min) blocks HBV preS1-mediated adhesion to HepG2-hNTCP-C4 cells and interferes with the initial step of viral invasion[1].
NPD8716 (200 μM) specifically inhibits NTCP-mediated viral entry, as it blocks HDV infection in HepG2-hNTCP-C4 cells but does not suppress HCV infection in Huh-7.5.1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2-hNTCP-C4 cells
-
Concentration:200 μM
-
Incubation Time:30 min
-
Result:Drastically reduced the attachment of TAMRA-labeled preS1 peptide to HepG2-hNTCP-C4 cells, similar to the inhibition caused by unlabeled preS1 peptide.
Chemical Information
-
CAS No. 956944-02-8
-
분자량 449.56
-
화학식 C23H31NO6S
-
SMILES
CC=1C=2C(=CC(OCC(N[C@@H](CCSC)C(O)=O)=O)=CC2)OC(=O)C1CCCCCC
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NPD8716 Related Classifications
HY-115668 Related Classifications
Powered by Bioz